Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
Andrew Blauvelt, Mark Lebwohl, Tomotaka Mabuchi, Ann N. Leung, Alyssa Garrelts, Heidi M. Crane, Hany Elmaraghy, Himanshu J. Patel, Terri Ridenour, Kyoungah See, Gaia Gallo, C. Paul
Topics & Concepts
IxekizumabMedicineRandomized controlled trialTerm (time)Internal medicineDermatologyPsoriasisPsoriatic arthritisPhysicsSecukinumabQuantum mechanicsPsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsInflammatory Bowel Disease